An Open-label Trial, Enrolling Subjects Aged 6 Years to Less Than 18 Years Suffering From Pain Requiring Prolonged Release Opioid Treatment, to Evaluate the Safety and Efficacy of Tapentadol PR Versus Morphine PR, Followed by an Open-label Extension

Trial Profile

An Open-label Trial, Enrolling Subjects Aged 6 Years to Less Than 18 Years Suffering From Pain Requiring Prolonged Release Opioid Treatment, to Evaluate the Safety and Efficacy of Tapentadol PR Versus Morphine PR, Followed by an Open-label Extension

Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 01 Dec 2017

At a glance

  • Drugs Tapentadol (Primary) ; Morphine
  • Indications Pain
  • Focus Therapeutic Use
  • Sponsors Grunenthal
  • Most Recent Events

    • 28 Nov 2017 Planned End Date changed from 1 Dec 2018 to 1 Nov 2018.
    • 28 Nov 2017 Status changed from recruiting to active, no longer recruiting.
    • 04 Oct 2017 Planned End Date changed from 1 Oct 2017 to 1 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top